Company Overview and News

Deadline for SOBA extended

COMPANIES hoping for a chance to be recognised at The Star Outstanding Business Awards (SOBA) 2018 will have more time to prepare their applications as the submission deadline has been extended to Oct 26.
6084 BSMAF 1818

How corporate leaders can build trust within the organisation

PETALING JAYA: Trust plays a strategic role in businesses today. With incidences of fraud becoming rampant, building trust is key to growing a sustainable business that can go beyond borders.

Design Thinking Masterclass workshop on Oct 17

PETALING JAYA: Challenges faced by today’s businesses have become more complicated, requiring business owners and executives to apply creative problem solving methods to come up with innovative solutions.

Leverage data to go further

Data driven: (from left) Moderator MAICCI secretary-general Datuk Dr A T Kumararajah discusses the use of data with Ng, Meehan and Teh.
6084 0181

Leverage data to go further

Data driven: (from left) Moderator MAICCI secretary-general Datuk Dr A T Kumararajah discusses the use of data with Ng, Meehan and Teh.
6084 0181

Minister to meet telecos to discuss role in wiring up Malaysia

Front row, from left: The Star Media Group Bhd group MD and CEO Wong Chun Wai, Communications and Multimedia Minister Gobind Singh Deo and Malaysian Advertisers Association (MAA) members were the guests at the MAA-World Federation of Advertisers (WFA) Digital Governance Forum. Other guests included Malaysian Communications and Multimedia Commission (MCMC) chairman Al-Ishsal Ishak (second row, left) , CFM chairman Mohamad Yusrizal Yusoff (second row, middle) and MAA vice-president Claudian Navin Stanislaus.
6084 4863 5347 6888 TNABY AXXTF MYTEF TNABF

Cover Story: ‘Our strategy is working’

2018-10-04 theedgemarkets
GROUP chief operating officer Roy Tan talks about Star Media engaging its audience, politics, people, profit and property

Cover Story: Transforming A media giant

2018-10-04 theedgemarkets
THE 15th floor of Menara Star is a curious mix of traditional stateliness and technological progress.
6084 CNHDF BSMAF 5HJ 1818

Accenture MD encourages SMEs to go the digital way

Accenture country managing director, Azwan Baharuddin delivered his keynote address at the Star SME Biz ThinkTank 2018 at New World Petaling Jaya Hotel. - AZMAN GHANI/The Star

Independent journalism seen to benefit media firms in long term

2018-10-01 theedgemarkets
Media sector Maintain neutral: The Malaysian Insight on Sept 6 reported, citing sources, that Prime Minister Tun Dr Mahathir Mohamad was mulling a ruling to cap political parties’ ownership of mainstream media companies at 10%.
4502 5754 6084 MIAHF

Ride upside of technology

APPS, smart systems, automation – these are only the beginning of what industry captains say may be an eventful journey towards having a business that is digitally supported and enabled.
6084 0181

Programmatic advertising seen growing ... but slowly

“Our first strategy would be to consolidate all the different ads from various publisher websites onto one single publisher space where potential buyers may extract the creatives from one source, instead of various ones,” Google Malaysia head of platform solution Stanley Lim (pic) said during his talk.

SMEs need to ride digital wave to progress

DISRUPTION is becoming a common term in business. Rapid development in technology and fast-changing consumer trends are pushing companies to look at different ways to reach out to their customers and lower cost to ensure that their business are not losing out.

Improving revenue with programmatic advertising

Priya: Harnessing the right data enables brands to reach out and connect with the right customers at the right time.

Transforming a media giant

2018-09-22 theedgemarkets
Star Media Group Bhd chief operating officer Roy Tan has been tasked with reshaping the newspaper company that has been hard hit by the digital disruption of print media.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...